Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists scan brains to uncover cannabinoid receptor secrets in mental illness and addiction

NCT ID NCT01730781

Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses a special PET scan tracer called [11-C]OMAR to measure cannabinoid receptors in the brain. Researchers will compare healthy volunteers to people with schizophrenia, cannabis dependence, PTSD, opioid use disorder, and other conditions. The goal is to understand how these receptors differ across disorders, which may inform future research. Participants receive one or more PET scans, and cannabis users will be scanned at different stages of abstinence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[11-C]OMAR (a radioactive tracer for PET scans)
What this could lead to
If successful, this could help researchers understand how brain cannabinoid receptors differ in various mental health and addiction conditions, potentially guiding future treatments.
What could go wrong
This is an observational imaging study, not a treatment trial. It is early-stage research and may not directly lead to new therapies. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Jul 2010

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is composed of schizophrenia, cannabis dependence, prodromal for psychotic illness, family history of alcoholism, healthy volunteers, Post-Traumatic Stress Disorder and Opioid Use Disorder.

Ages

18 to 55 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males ages 18-55 * For cannabis users: * Willing to abstain from cannabis use for four weeks * For schizophrenia: * Meets DSM-IV-TR criteria for schizophrenia or schizoaffective disorder * For prodrome for psychotic illness: * Meets SIPS criteria for prodromal syndrome * For family history positive: * First degree relative with alcoholism * For Post-Traumatic Stress Disorder * Meets DSM-IV-TR criteria for PTSD * For OUD * Meets DSM-IV-TR criteria for Opioid Use Disorder Exclusion Criteria: * Current neuro-psychiatric illness (including cannabis dependence) or severe systemic disease. Cannabis use disorder is permitted in the cannabis dependent group. Schizophrenia and schizoaffective disorder is permitted in the schizophrenia group. Psychotic symptoms are permitted in the prodromal group. Post-Traumatic Stress Disorder is permitted in the PTSD group and Opioid Use Disorder is permitted in the OUD group. * Presence of ferromagnetic metal in the body or heart pacemaker * Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits * Are claustrophobic

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis dependence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence opiate dependence post-traumatic stress disorder schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis dependence Family history of alcoholism Healthy control Opioid use disorder Post traumatic stress disorder Prodromal for psychotic illness Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Connecticut Mental Health Center, Clinical Neuroscience Research Unit

    RECRUITING

    New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.